Iron Deficiency Anemia

Iron deficiency anemia (IDA) is the most common cause of anemia worldwide, resulting from insufficient iron stores to support adequate hemoglobin synthesis and red blood cell production. Clinically significant in both resource-rich and resource-limited countries, IDA affects approximately 2-3 billion people globally, with higher prevalence in women of reproductive age, children, and populations with limited dietary iron access or chronic blood loss. The condition is particularly important for board examination preparation because it requires systematic identification of the underlying cause—mere iron supplementation without diagnosis of the etiology may delay detection of serious pathology such as gastrointestinal malignancy. Understanding the iron metabolism pathway, diagnostic criteria, and evidence-based approach to identifying causes is essential for clinical practice and USMLE success.

Iron deficiency anemia develops through a predictable sequence of events reflecting progressive depletion of total body iron stores, with characteristic progression from iron depletion to iron-deficient erythropoiesis to frank anemia.

The human body contains approximately 3-4 g of total iron, with ~65% in hemoglobin, 10% in myoglobin, and 20-30% in storage forms (ferritin and hemosiderin). Daily iron loss (~1-2 mg in men, 1-2 mg in menstruating women) is compensated by dietary absorption of ~1-2 mg daily. Dietary iron exists in two forms: heme iron (10-30% bioavailability, found in animal products) and non-heme iron (2-20% bioavailability, found in plant sources). Iron absorption occurs primarily in the proximal duodenum and proximal jejunum through divalent metal transporter-1 (DMT1), which requires acidic pH for optimal function. Ferrous iron (Fe²⁺) is preferentially absorbed over ferric iron (Fe³⁺), hence gastric acid and reducing substances (ascorbic acid) enhance absorption while inhibitors (phytates, tannins, calcium, proton pump inhibitors) decrease it. Hepcidin, the master iron-regulatory hormone produced by hepatocytes, decreases intestinal iron absorption and increases iron sequestration when iron stores are adequate, and conversely decreases when stores are depleted.

The earliest manifestation of iron deficiency is depletion of storage iron in bone marrow and hepatic macrophages. During this stage, serum ferritin levels fall below 15 μg/L (although ferritin is an acute phase reactant and may be falsely elevated), and bone marrow staining with Prussian blue reveals absent iron stores. Serum iron, total iron-binding capacity (TIBC), transferrin saturation, and hemoglobin remain normal at this stage because the body can maintain adequate iron delivery to erythroid precursors from circulating transferrin. This stage is clinically silent and requires formal iron studies for detection. The lack of clinical symptoms makes this stage particularly important in screening at-risk populations.

As iron stores become completely depleted, circulating iron delivery becomes insufficient for normal hemoglobin synthesis despite normal hemoglobin levels. Serum iron falls (<60 μg/dL), TIBC rises (>360 μg/dL), and transferrin saturation decreases (<20%). Increased erythropoietin stimulation drives increased iron demand that cannot be met, leading to upregulation of DMT1 and transferrin receptors on erythroid precursors. Microcytic erythropoiesis begins as the MCV starts to fall, and serum soluble transferrin receptor increases (>28 nmol/L), reflecting increased erythroid iron demand. Serum ferritin becomes markedly reduced (<12 μg/L). Hemoglobin may still be in the low-normal range (11-12 g/dL), making this a critical diagnostic window where clinical suspicion must drive investigation.

When circulating iron becomes insufficient for daily hemoglobin synthesis, frank anemia develops. The hemoglobin progressively falls as erythropoietin-driven but iron-limited erythropoiesis produces progressively smaller red blood cells. The MCV falls below 80 fL, and with severe deficiency, may drop to 50-60 fL. Red cell distribution width (RDW) increases, reflecting heterogeneity in red cell size. Peripheral blood smear demonstrates hypochromic (pale central pallor), microcytic cells with occasional target cells and pencil cells (severely hypochromic cells). Reticulocyte count is inappropriately low for the degree of anemia, reflecting limited iron availability for new hemoglobin synthesis despite high erythropoietin levels. This represents a crucial pathophysiologic point: despite maximal erythropoietin stimulation, reticulocytes cannot be generated in normal numbers because the fundamental substrate (iron for heme synthesis) is unavailable. The iron profile is diagnostic: serum ferritin <15 μg/L, serum iron <40 μg/dL, TIBC >360 μg/dL, transferrin saturation <15%, and soluble transferrin receptor markedly elevated.

Beyond effects on hemoglobin synthesis, iron deficiency impairs function of iron-dependent enzymes and proteins throughout the body, explaining systemic manifestations. Cytochrome P450 enzymes, catalase, peroxidase, and other iron-dependent oxidative enzymes function suboptimally, impairing cellular energy metabolism. Myoglobin insufficiency impairs oxygen delivery in skeletal and cardiac muscle, contributing to exercise intolerance and potentially to dilated cardiomyopathy in severe chronic deficiency. Collagen and elastin synthesis are impaired due to reduced activity of iron-dependent prolyl hydroxylase, contributing to the brittle nails and spoon nails (koilonychia) seen in chronic deficiency. Neurotransmitter synthesis is impaired, potentially contributing to cognitive and behavioral effects, particularly in children. Immune function is compromised through effects on myeloperoxidase and other antimicrobial oxidases, increasing infection risk.

The anemia triggers compensatory mechanisms including increased cardiac output and increased oxygen extraction by tissues. In chronic IDA, increased 2,3-DPG production shifts the hemoglobin-oxygen dissociation curve rightward, improving tissue oxygen delivery at any given hemoglobin level. These compensatory mechanisms often allow remarkable tolerance of severe anemia if onset is gradual, explaining why some patients are asymptomatic with hemoglobin levels of 7-8 g/dL if the anemia developed insidiously. However, acute severe iron loss (e.g., gastrointestinal hemorrhage) triggers shock and organ dysfunction at much higher hemoglobin levels because compensatory mechanisms cannot fully develop.

Iron deficiency anemia results from negative iron balance through three primary mechanisms: insufficient iron intake/absorption, increased iron losses, or increased iron requirements. Identifying the specific etiology is paramount because treating IDA as an isolated condition while missing serious underlying pathology (particularly occult malignancy) is a common clinical pitfall.

Chronic blood loss exceeding the body's capacity to replace iron is the most frequent cause in developed nations, particularly in non-menstruating populations. Gastrointestinal sources account for the majority: peptic ulcer disease (most common in older patients on NSAIDs or with H. pylori), vascular malformations (particularly in the elderly—angiodysplasia of the colon and small bowel), inflammatory bowel disease (especially ulcerative colitis with significant mucosal bleeding), and colorectal or upper GI malignancy. Occult GI bleeding, often from malignancy, may cause anemia before any overt symptoms, emphasizing the importance of systematic evaluation. Menorrhagia (heavy menstrual bleeding >80 mL/cycle) is the leading cause in women of reproductive age; mechanisms include anovulation with prolonged unopposed estrogen stimulation and abnormalities of hemostasis. Hematuria from urinary tract malignancy, chronic kidney disease, or bleeding disorders causes IDA primarily in patients with significant proteinuria or recurrent gross hematuria. Repeated phlebotomy, blood donations (particularly in frequent donors), or other iatrogenic blood loss contributes, especially in developed countries with blood donation programs. Pulmonary hemorrhage from conditions like idiopathic pulmonary hemosiderosis or vasculitis causes IDA through repeated alveolar bleeding and iron loss in sputum. The key clinical pearl is that in any patient with IDA, particularly men and postmenopausal women, systematic investigation for occult GI bleeding is mandatory—this drives the need for upper endoscopy and colonoscopy.

Insufficient dietary iron intake is particularly prevalent in developing countries and contributes significantly to IDA in vulnerable populations. Strict vegetarians and vegans ingest primarily non-heme iron with lower bioavailability; combined with higher levels of iron absorption inhibitors (phytates, polyphenols), absorption may be inadequate despite reasonable total iron content. Severe malnutrition and poverty-associated food insecurity cause combined deficiencies of iron and other nutrients. Malabsorption disorders profoundly impair iron absorption: celiac disease (both overt and latent forms) causes IDA through villous atrophy and impaired iron absorption despite adequate intake; untreated celiac disease is now recognized as a common cause of refractory IDA in developed countries. Inflammatory bowel disease impairs iron absorption independent of blood loss effects. Post-gastrectomy or post-bypass surgery patients have reduced acid production (limiting non-heme iron solubility and absorption) and shortened intestinal transit time. Achlorhydria from atrophic gastritis, autoimmune gastritis, or chronic PPI use eliminates the acidic environment required for iron solubilization and absorption. H. pylori infection causally impairs iron absorption through multiple mechanisms. Pernicious anemia-associated atrophic gastritis frequently presents with concurrent IDA. The critical concept is that iron deficiency from malabsorption typically presents with normal or elevated ferritin initially (because ferritin rises with intestinal inflammation), distinguishing it from primary iron deficiency—serologic testing or endoscopy is required for diagnosis.

Pregnancy substantially increases iron demands, particularly in the second and third trimesters when fetal iron accumulation accelerates; despite physiologic increases in plasma volume that lower hemoglobin concentration, true anemia reflects inadequate iron stores. Lactation also increases requirements. Rapid growth in infancy and childhood increases demands; term infants deplete placental iron stores by 4-6 months, and continued demand for hemoglobin synthesis during rapid growth makes this period high-risk for IDA. Adolescent growth spurts increase iron needs. Frequent blood donors, if not spacing donations appropriately or supplementing iron, may develop IDA despite normal absorption and intake. Athletes, particularly endurance athletes, have increased iron losses through sweat and may develop IDA even with adequate intake. The critical clinical point is that in these populations, distinguishing between IDA and other causes of anemia (such as anemia of chronic disease) is essential for appropriate management.

Many patients have multiple contributing factors. A woman with menorrhagia on chronic NSAIDs for arthritis may have both hemorrhagic losses (menstrual) and GI bleeding with concurrent malabsorption from celiac disease—all contributing to severe IDA. Patients with chronic kidney disease have both decreased erythropoietin production and blood loss from dialysis, compounded by any dietary or absorption issues. The elderly frequently have multiple contributors: chronic NSAID use, occult GI malignancy, atrophic gastritis, and polypharmacy (PPIs impairing absorption). This complexity underscores the importance of detailed history and systematic investigation rather than empiric iron supplementation.

The clinical manifestations of iron deficiency anemia reflect both the underlying etiology and the severity and acuity of the anemia. Symptoms may be minimal with gradual onset and good compensatory mechanisms, yet severe with rapid onset or poor reserve (as in cardiovascular or pulmonary disease).

Fatigue and Weakness represent the cardinal symptom, reflecting both reduced oxygen carrying capacity and impaired cellular metabolism from iron deficiency. Fatigue is typically gradual in onset with chronic iron loss but may be abrupt with acute hemorrhage. Patients describe decreased exercise tolerance, shortness of breath with exertion (dyspnea on exertion), and inability to perform previously routine tasks. The severity correlates imperfectly with hemoglobin level due to compensatory mechanisms—some patients are relatively asymptomatic at hemoglobin 7-8 g/dL if anemia developed insidiously, while others are profoundly symptomatic at 10-11 g/dL if onset was acute.

Dyspnea on Exertion results from increased cardiopulmonary demands imposed by anemia; patients attempt to increase cardiac output to deliver adequate oxygen, and respiratory rate increases to augment oxygen extraction. May progress to orthopnea or paroxysmal nocturnal dyspnea in severe cases or in patients with underlying cardiac disease. Particularly concerning in patients with coronary artery disease, as anemia-induced tachycardia and increased cardiac demands may precipitate angina.

Palpitations arise from compensatory tachycardia and increased cardiac output; patients describe heart racing, particularly with exertion or emotional stress. May be accompanied by chest discomfort or arrhythmia awareness.

Dizziness and Syncope reflect reduced cerebral oxygen delivery. Orthostatic hypotension may occur due to impaired compensatory vasoconstriction. Syncope is unusual unless anemia is severe or occurs with acute hemorrhage.

Cognitive and Behavioral Changes are particularly notable in children, including decreased school performance, impaired concentration, and behavioral abnormalities. Mechanisms include impaired neurotransmitter synthesis and reduced cerebral oxygen delivery. Less commonly appreciated in adults but may contribute to reported cognitive impairment in severe IDA.

Pica (craving of non-food items) is a characteristic symptom of iron deficiency, present in 10-20% of severely iron-deficient patients. Patients may crave ice (pagophagia, most common), starch, soil (geophagia), or other non-nutritive substances. The pathophysiology remains unclear but may relate to iron-dependent enzymes in taste and smell perception, or to behavioral effects of iron deficiency. Pica resolves with iron repletion, making it potentially useful for monitoring treatment response.

Restless Leg Syndrome occurs with increased frequency in IDA, characterized by uncomfortable sensations in the legs (described as crawling, creeping, or tingling) that worsen with inactivity and improve with movement, particularly at night. Iron supplementation often dramatically improves or resolves symptoms.

Dysphagia may develop with severe chronic IDA due to formation of esophageal webs (Plummer-Vinson syndrome), which is now uncommon in developed countries. Presents with difficulty swallowing solid foods, particularly meats, with risk of impaction.

Pallor of mucous membranes, conjunctivae, and nail beds reflects reduced hemoglobin and is a crude but nonspecific sign of anemia. More apparent in severe anemia (Hgb <7 g/dL) but absent in mild-moderate disease.

Koilonychia (spoon nails) represents a distinctive finding in chronic severe iron deficiency, where nails become thin, brittle, and concave with upturned edges resembling spoons. Results from impaired collagen and keratinous protein synthesis due to iron-dependent enzyme dysfunction. Develops only after months to years of severe deficiency and regresses slowly with iron repletion. While highly specific for chronic IDA, it is uncommon in modern practice due to earlier diagnosis and treatment.

Tachycardia is nearly universal in symptomatic IDA as the body attempts to increase cardiac output. May be pronounced, particularly with exertion. Normalizes with iron repletion and is a useful marker of treatment response.

Tachypnea similarly represents a compensatory response to maintain oxygen delivery; may progress to resting tachypnea in severe anemia.

Systolic Flow Murmur is common in moderate-severe anemia (particularly with Hgb <7 g/dL), reflecting increased cardiac output and turbulent flow across the aortic valve. Disappears with anemia correction, helping distinguish from organic cardiac valve disease.

Glossitis and Glossal Atrophy (smooth, beefy red tongue) occasionally occur, though are less common than in vitamin B12 or folate deficiency. Reflects mucosal atrophy from iron deficiency.

Angular Cheilitis (cracks at the corners of the mouth) may occur with severe chronic iron deficiency, often with oral